ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Section A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Further participants will be enrolled within the determined monotherapy dosign regimen. In Section B, individuals will acquire oral ruxolitinib and ABBV-744 might be offered as "increase-on" therapy. In Section C, contribut